Oral Mucosa
Conditions
Keywords
painful post-traumatic trigeminal neuropathy, neuropathic pain, neuropathic odontalgia, gingival biopsy
Brief summary
The DIAMOND study aims to investigate the presence and diagnostic relevance of potential biomarkers of the blood-nerve barrier disruption as surrogate markers of painful post-traumatic trigeminal neuropathic pain in patients presenting with neuropathic odontalgia. The first part of the study explores the proof-of-concept and technical feasibility of intra-epithelial nerve fiber immunostaining in gingival/oral mucosa biopsies and the potential presence of these biomarkers in healthy patients (baseline condition).
Detailed description
Painful Post-Traumatic Trigeminal Neuropathy (PPTTN) defines a neuropathic painful condition affecting the orofacial region, following local nerve trauma, usually secondary to dental treatments (tooth avulsion, root canal treatments….). It often presents as odontalgia of atypical presentation, unresponsive to conventional treatments. The diagnostic is often complex (and often is a diagnosis of elimination), leading to unnecessary iatrogenic dental treatments and insufficient pain relief. This study aims to explore potential new markers of PPTTN, based on a translational approach following previous preclinical work that showed the importance of the disruption of the blood-nerve barrier in generating post-traumatic neuropathic pain. Several markers of such disruption have been highlighted (such as Claudin-5, Patched-1 and Frizzled-7) that could be specifically downregulated in neuropathic pain conditions (as compared to inflammatory neuritis conditions). As such, these markers could be interesting biomarkers of neuropathic pain. This study aims to explore the presence (and absence) of such markers in healthy vs neuropathic patients respectively. The first part of the study investigates the technical feasibility of intra-epithelial nerve fiber staining in oral mucosa/gingiva specimens collected in healthy patients (undergoing routine oral surgery procedures) and the immunoreactivity/presence of such biomarkers in those specimens.
Interventions
OTHERImmunostaining
Immunostaining of oral mucosa/gingiva samples
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adult patients (over 18 years old) requiring an oral/dental surgical intervention that will generate gingival/mucosal tissue elimination (as part of the normal surgical procedure)
Exclusion criteria
* Patient with a diagnosed odontalgia * Patient with Painful Post-Traumatic Trigeminal Neuropathy (PPTTN) * Patient with unexplained pains or a neuropathic pain regardless of its location * Patient under guardianship or trusteeship * Patient who refuses to give his/her non-opposition to participate to the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patched-1 Western Blot concentration | Baseline | Patched-1 will be measured in oral mucosa/gingiva samples using Western Blot |
| Patched-1 immunohistochemistry concentration | Baseline | Patched-1 will be measured in oral mucosa/gingiva samples using immunohistochemistry (IHC) |
| Patched-1 ELISA concentration | Baseline | Patched-1 will be measured in oral mucosa/gingiva samples using ELISA |
| Frizzled-7 Western Blot concentration | Baseline | Frizzled-7 will be measured in oral mucosa/gingiva samples using Western Blot |
| Frizzled-7 immunohistochemistry concentration | Baseline | Frizzled-7 will be measured in oral mucosa/gingiva samples using immunohistochemistry (IHC) |
| Frizzled-7 ELISA concentration | Baseline | Frizzled-7 will be measured in oral mucosa/gingiva samples using ELISA |
| Claudin-5 Western Blot concentration | Baseline | Claudin-5 will be measured in oral mucosa/gingiva samples using Western Blot |
| Claudin-5 immunohistochemistry concentration | Baseline | Claudin-5 will be measured in oral mucosa/gingiva samples using immunohistochemistry (IHC) |
| Claudin-5 ELISA concentration | Baseline | Claudin-5 will be measured in oral mucosa/gingiva samples using ELISA |
Countries
France
Contacts
Primary ContactNathan MOREAU, DDS, PhD
Outcome results
None listed